His primary areas of investigation include Immunology, Immune system, Immunotherapy, Vaccinia and Carcinoembryonic antigen. Many of his studies on Immunology apply to Prostvac as well. His studies deal with areas such as Clinical trial, Combination therapy, Pharmacology and Docetaxel as well as Immune system.
He has researched Immunotherapy in several fields, including Cancer cell, Cytotoxic T cell, Cancer research and Combined Modality Therapy. His Cancer research research incorporates elements of MHC class I and Chemotherapy. His Vaccinia research integrates issues from Virology and Vaccination.
The scientist’s investigation covers issues in Immunology, Immunotherapy, Cancer research, Immune system and Antigen. James W. Hodge has included themes like Cancer, Carcinoembryonic antigen and Cytotoxic T cell in his Immunology study. His Immunotherapy research incorporates themes from Cancer cell, Chemotherapy, Pharmacology and Immunogenicity.
His study in Cancer research is interdisciplinary in nature, drawing from both Chimeric antigen receptor, MHC class I, Combination therapy and Antibody-dependent cell-mediated cytotoxicity. His Immune system study incorporates themes from Vaccinia and Radiation therapy. His Antigen research is multidisciplinary, incorporating elements of T cell, Viral vector, Vaccination, Vaccine therapy and Tumor antigen.
James W. Hodge spends much of his time researching Cancer research, Immunotherapy, Immune system, Chimeric antigen receptor and Antigen. His studies in Cancer research integrate themes in fields like CD16, Cancer, Cell therapy and Cancer immunotherapy. His Immunotherapy research includes elements of T cell, Primary tumor and CD8.
His study on Immune system is mostly dedicated to connecting different topics, such as Combination therapy. His work in Chimeric antigen receptor covers topics such as PD-L1 which are related to areas like Myeloid, Growth inhibition and Tumor control. His Antigen research focuses on Immune checkpoint and how it relates to Tumor antigen, Immunodominance, Durvalumab and Ovarian cancer.
James W. Hodge mainly investigates Cancer research, Immune system, Immunotherapy, Immunogenic cell death and Cancer cell. The study incorporates disciplines such as Head and neck squamous-cell carcinoma and Antibody-dependent cell-mediated cytotoxicity in addition to Cancer research. His research integrates issues of Interferon and Antibody in his study of Immune system.
Immunotherapy is a subfield of Cancer that James W. Hodge studies. His Immunogenic cell death research is multidisciplinary, relying on both Acquired immune system, Antigenicity, Pattern recognition receptor, Intracellular and Adjuvanticity. His Cancer cell study integrates concerns from other disciplines, such as Squamous carcinoma, Neuroscience and Antigen presentation.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
Eric A. Reits;James W Hodge;Carla A Herberts;Tom A M Groothuis.
Journal of Experimental Medicine (2006)
Consensus guidelines for the detection of immunogenic cell death
Oliver Kepp;Laura Senovilla;Ilio Vitale;Erika Vacchelli.
Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes
Charlie T. Garnett;Claudia Palena;Mala Chakarborty;Kwong-Yok Tsang.
Cancer Research (2004)
Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy
Mala Chakraborty;Scott I. Abrams;Kevin Camphausen;Kebin Liu.
Journal of Immunology (2003)
External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing.
Mala Chakraborty;Scott I. Abrams;C. Norman Coleman;Kevin Camphausen.
Cancer Research (2004)
Phase I Study of Sequential Vaccinations With Fowlpox-CEA(6D)-TRICOM Alone and Sequentially With Vaccinia-CEA(6D)-TRICOM, With and Without Granulocyte-Macrophage Colony-Stimulating Factor, in Patients With Carcinoembryonic Antigen–Expressing Carcinomas
John L. Marshall;James L. Gulley;Philip M. Arlen;Patricia K. Beetham.
Journal of Clinical Oncology (2005)
Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer
James L. Gulley;Philip M. Arlen;Anne Bastian;Steven Morin.
Clinical Cancer Research (2005)
A triad of costimulatory molecules synergize to amplify T-cell activation.
James W. Hodge;Helen Sabzevari;Alicia Gómez Yafal;Linda Gritz.
Cancer Research (1999)
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.
James L. Gulley;Philip M. Arlen;Ravi A. Madan;Kwong-Yok Tsang.
Cancer Immunology, Immunotherapy (2010)
Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing
Sofia R. Gameiro;Momodou L. Jammeh;Max M. Wattenberg;Kwong Y. Tsang.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: